Alkahest, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alkahest.com
Clinical Trials
23
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05038020
- Locations
- 🇺🇸
Site 132, Phoenix, Arizona, United States
🇺🇸Site 136, Phoenix, Arizona, United States
🇺🇸Site 123, Glendale, California, United States
Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
- Conditions
- End-Stage Renal Disease
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04985383
- Locations
- 🇺🇸
Renal Consultant Medical Group, Granada Hills, California, United States
🇺🇸Valley Renal Medical Group Research, Northridge, California, United States
🇺🇸US Renal Care, Gallup, New Mexico, United States
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
- Conditions
- Cognitive ImpairmentEnd Stage Renal Disease
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04527328
- Locations
- 🇺🇸
Renal Consultants Medical Group, Granada Hills, California, United States
🇺🇸Valley Renal Medical Group, Northridge, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
- Conditions
- Pemphigoid, Bullous
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04499235
- Locations
- 🇩🇪
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie, Dresden, Germany
🇩🇪Universitätsklinikum Düsseldorf Klinik für Dermatologie, Düsseldorf, Germany
🇩🇪Universitätsklinikum Erlangen - Hautklinik, Erlangen, Germany
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Alkahest, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04369430
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Henry Ford Hospital West Bloomfield, West Bloomfield, Michigan, United States
🇺🇸Movement Disorder Clinic of Oklahoma PLLC, Tulsa, Oklahoma, United States
- Prev
- 1
- 2
- 3
- Next